drugset / Trial / NCT03628053
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.
Timeline
- Start
- 2020-06-05
- Primary completion
- 2025-10-08
- Completion
- 2026-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Blinatumomab | Monoclonal antibody | — | — |
| Comparator | Inotuzumab | Other / unclassified | — | — |
| Subject | Tisagenlecleucel | Cell therapy | — | — |